HC Wainwright Predicts Fractyl Health FY2030 Earnings

Fractyl Health, Inc. (NASDAQ:GUTS) – Analysts at HC Wainwright issued their FY2030 earnings estimates for shares of Fractyl Health in a research report issued on Monday, January 26th. HC Wainwright analyst J. Pantginis expects that the company will earn $0.79 per share for the year. HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Fractyl Health’s current full-year earnings is ($1.61) per share.

Fractyl Health (NASDAQ:GUTS) last issued its earnings results on Wednesday, November 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01).

Several other equities research analysts have also recently commented on the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a research report on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fractyl Health in a research note on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $7.40.

Fractyl Health Stock Down 2.8%

Shares of NASDAQ GUTS opened at $2.12 on Tuesday. Fractyl Health has a twelve month low of $0.82 and a twelve month high of $3.03. The firm has a market cap of $290.52 million, a P/E ratio of -0.93 and a beta of 1.62. The company has a 50 day moving average of $2.00 and a 200 day moving average of $1.53.

Institutional Investors Weigh In On Fractyl Health

Hedge funds have recently made changes to their positions in the stock. Catalyst Funds Management Pty Ltd purchased a new position in Fractyl Health in the second quarter valued at about $26,000. Bank of America Corp DE boosted its holdings in shares of Fractyl Health by 23.5% in the 3rd quarter. Bank of America Corp DE now owns 88,634 shares of the company’s stock valued at $141,000 after buying an additional 16,856 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Fractyl Health in the 2nd quarter valued at about $31,000. FNY Investment Advisers LLC purchased a new position in shares of Fractyl Health in the 3rd quarter worth approximately $31,000. Finally, Scientech Research LLC bought a new position in shares of Fractyl Health during the 3rd quarter worth approximately $49,000.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.